Kurt Jackson, MD
Retina Specialist · Livingston, NJNPI 1619161858
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,740 of the $10,643 with a category attached, or 63.3%. It is spread thinly across 25 manufacturers, the largest accounting for just 22.2%.
Across 204 payments — averaging $52.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$2K
- AbbVie$2K
- Genentech, Inc.$2K
- Bausch & Lomb Americas Inc.$796
- Apellis Pharmaceuticals, Inc.$626
- Regeneron Healthcare Solutions, Inc.$552
- plus $3K from 19 others
Across 9 payments — averaging $20,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$152K
- Roche TCRC, Inc.$34K
What the payments were for
- Travel & lodging$3,90337%
- Food & beverage$6,74063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 3 | $2,358 |
| AbbVie(2 entities) | 50 | $1,932 |
| Genentech, Inc. | 5 | $1,853 |
| Bausch & Lomb Americas Inc. | 24 | $796 |
| Apellis Pharmaceuticals, Inc. | 5 | $626 |
| Regeneron Healthcare Solutions, Inc. | 6 | $552 |
| Dompe US, Inc. | 22 | $492 |
| Biotissue Holdings Inc. | 9 | $347 |
| Astellas Pharma US Inc | 10 | $264 |
| Oyster Point Pharma, Inc. | 12 | $203 |
| Sight Sciences, Inc. | 2 | $182 |
| Genentech USA, Inc. | 10 | $175 |
| Tarsus Pharmaceuticals, Inc. | 9 | $164 |
| Alimera Sciences, Inc. | 7 | $131 |
| Coherus Oncology, Inc. | 4 | $115 |
| ANI Pharmaceuticals, Inc. | 5 | $85 |
| Sun Pharmaceutical Industries Inc. | 5 | $83 |
| Alcon | 4 | $82 |
| Mallinckrodt Hospital Products Inc. | 4 | $71 |
| Thea Pharma Inc. | 2 | $39 |
| Novartis | 2 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Novo Nordisk | 1 | $15 |
| Harrow Eye, LLC | 1 | $15 |
| Tearlab Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$4,198
- DURYSTA$614
- XEN GLAUCOMA TREATMENT SYSTEM$349
- EYLEA$260
- EYLEA HD$259
- AmnioGraft$210
- OMNI(R) SURGICAL SYSTEM (US)$140
- enVista MX60 IOL$137
- Izervay$123
- Oxervate$121
- Prokera$103
How this compares
$10,643 in reported general payments places this provider in the 70th percentile of 35 retina specialist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 161 | $7,500 |
| LumiganBimatoprost | 15 | $6,072 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $1,877 |
| Timolol Maleate | 32 | $801 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $788 |
| Latanoprost | 44 | $442 |
| Ketorolac Tromethamine | 13 | $381 |
| Brimonidine Tartrate | 17 | $227 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 19 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $1,932 | $6,07215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 retina specialist providers in New Jersey.
Other retina specialist in Livingston
- Tian XiaLivingston$6K
- Eric KanterLivingston$725
- Howard FineNew Brunswick$955K
- Joshua MaliFlemington$230K
- Jonathan PrennerNew Brunswick$215K
- Leonard FeinerUnion$72K
- Daniel RothNew Brunswick$61K
- Sumit ShahNew Brunswick$41K
- Vatsal DoshiMillburn$32K
- Ravi PatelToms River$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.